BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Akeso’s Ivonescimab Outperforms Pembrolizumab in Phase III, Wins NMPA Approval for First-Line PD-L1-Positive NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has re...

April 28, 2025 | News

Innovent Biologics Secures NMPA Approval for Limertinib as First-Line Therapy for EGFR-Mutated NSCLC in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

April 28, 2025 | News

Gene Solutions and Element Biosciences Forge Multiomics Collaboration to Expand Access to Genetic Testing Across Asia and Beyond

Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing acc...

April 23, 2025 | News

GC Cell Secures Exclusive Rights to DAAN Biotherapeutics’ Tumor Antigen-Specific Antibody for CAR-T and CAR-NK Therapies

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusi...

April 22, 2025 | News

Bristol Myers Squibb’s Opdivo Plus Yervoy Wins FDA Nod as First-Line Treatment for Advanced Liver Cancer

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® ...

April 14, 2025 | News

Mabwell’s B7-H3-Targeting ADC 7MW3711 Enters Phase Ib/II Trial in China for Advanced Solid Tumors

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) ha...

April 03, 2025 | News

Lunit Collaborates with U.S. National Cancer Institute to Advance AI-Driven Cancer Research

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the Nationa...

April 01, 2025 | News

Gene Solutions Achieves Landmark Validation for Asia’s First Clinically Proven Multi-Cancer Blood Test, SPOT-MAS

Gene Solutions, a leading biotech company in Asia, proudly announces a groundbreaking achievement in cancer early detection. Common cance...

March 27, 2025 | News

China’s Everest Gets FDA Clearance for First mRNA Cancer Vaccine EVM14

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer ...

March 25, 2025 | News

CStone Submits EMA Application to Expand Sugemalimab Use in Stage III Lung Cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submiss...

March 25, 2025 | News

Sermonix and Regor Therapeutics Forge Strategic Alliance to Advance Targeted Therapies for Metastatic Breast Cancer

Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mB...

March 25, 2025 | News

Akeso Showcases Positive Phase III Safety Run-In Data for Cadonilimab at SGO 2025 in Locally Advanced Cervical Cancer

Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...

March 24, 2025 | Report

Akeso’s Penpulimab Secures NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National ...

March 18, 2025 | News

Exicure Secures Australian Patent for Dual-Target Cancer Therapy Approach

Exicure, Inc. announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." ...

March 14, 2025 | News

Stay Connected